Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzydamine + cetylpyridine chloride is a fixed-dose combination drug primarily available as lozenges or orosoluble tablets for the local treatment of sore throat and minor infections of the mouth and throat. Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, local anesthetic, and mild antiseptic properties. Its mechanism is distinct from typical NSAIDs: it inhibits proinflammatory cytokine synthesis (such as TNFα, IL-1β, and MCP-1) and modulates neuronal excitability. Cetylpyridine chloride (CPC) is a cationic quaternary ammonium compound with broad-spectrum antiseptic and antimicrobial action, rapid bactericidal effect on gram-positive bacteria, and fungicidal effect on yeasts. The combination provides symptomatic relief in upper respiratory tract infections, reducing throat pain quickly and for at least several hours after administration. It is indicated for relief of throat pain, gingivitis, stomatitis, and prevention/treatment of local oropharyngeal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzydamine + cetylpyridine chloride.